دورية أكاديمية
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease
| العنوان: | The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease |
|---|---|
| المؤلفون: | Neumann, U, Ufer, M, Jacobson, LH, Rouzade-Dominguez, M-L, Huledal, G, Kolly, C, Luond, RM, Machauer, R, Veenstra, SJ, Hurth, K, Rueeger, H, Tintelnot-Blomley, M, Staufenbiel, M, Shimshek, DR, Perrot, L, Frieauff, W, Dubost, V, Schiller, H, Vogg, B, Beltz, K, Avrameas, A, Kretz, S, Pezous, N, Rondeau, J-M, Beckmann, N, Hartmann, A, Vormfelde, S, David, OJ, Galli, B, Ramos, R, Graf, A, Lopez, CL |
| بيانات النشر: | WILEY |
| سنة النشر: | 2018 |
| المجموعة: | The University of Melbourne: Digital Repository |
| الوصف: | The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. The BACE-1 inhibitor CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP-transgenic mice. Animal toxicology studies of CNP520 demonstrated sufficient safety margins, with no signs of hair depigmentation, retina degeneration, liver toxicity, or cardiovascular effects. In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose-dependent Aβ reduction in the cerebrospinal fluid. Thus, long-term, pivotal studies with CNP520 have been initiated in the Generation Program. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1757-4676 1757-4684 |
| العلاقة: | pii: emmm.201809316; Neumann, U., Ufer, M., Jacobson, L. H., Rouzade-Dominguez, M. -L., Huledal, G., Kolly, C., Luond, R. M., Machauer, R., Veenstra, S. J., Hurth, K., Rueeger, H., Tintelnot-Blomley, M., Staufenbiel, M., Shimshek, D. R., Perrot, L., Frieauff, W., Dubost, V., Schiller, H., Vogg, B. ,. Lopez, C. L. (2018). The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. EMBO MOLECULAR MEDICINE, 10 (11), https://doi.org/10.15252/emmm.201809316Test.; http://hdl.handle.net/11343/271258Test |
| الإتاحة: | https://doi.org/10.15252/emmm.201809316Test http://hdl.handle.net/11343/271258Test |
| حقوق: | CC BY ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: | edsbas.14D41425 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 17574676 17574684 |
|---|